Cystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina
|
|
- Ethel Burns
- 6 years ago
- Views:
Transcription
1 Cystic Fibrosis: Progress in Treatment Management Patrick A. Flume, M.D. Medical University of South Carolina
2 Disclosures Grant support Mpex Pharmaceuticals, Inc Gilead Sciences, Inc Bayer Healthcare AG Novartis Vertex Pharmaceuticals, Inc Pharmaxis Limited Boehringer Ingelheim Pharmaceuticals Savara Pharma KaloBios Cystic Fibrosis Foundation National Institutes of Health Consultant Gilead Vertex Pharmaceuticals, Inc Novartis Pharmaxis Limited Speaker s Bureau Genentech
3 Pathogenesis of CF Lung Disease Gene mutations Abnormal CFTR
4 Pathogenesis of CF Lung Disease Gene mutations CFTR quantity Abnormal CFTR Reduced ASL CFTR function
5 Pathogenesis of CF Lung Disease Gene mutations CFTR quantity CFTR function Reduced ASL Impaired MCC Obstruction
6 Airway Mucous Plugging in Cystic Fibrosis Used with permission J. Wagener, 2004.
7 Pathogenesis of CF Lung Disease Gene mutations CFTR quantity CFTR function Reduced ASL Impaired MCC Obstruction Infection
8 Respiratory Infections in CF Patients Cystic Fibrosis Foundation Patient Registry Annual Data Report. Bethesda, MD.
9 Pathogenesis of CF Lung Disease Gene mutations CFTR quantity CFTR function Reduced ASL Impaired MCC Obstruction Infection Inflammation
10 Inflammation in Bronchioalveolor Lavage Fluid Control Cystic Fibrosis Used with permission - J. Wagener, 2004.
11 Pathogenesis of CF Lung Disease Gene mutations CFTR quantity CFTR function Reduced ASL Impaired MCC Obstruction Infection Inflammation
12 Pathogenesis of CF Lung Disease Gene mutations CFTR quantity CFTR function Reduced ASL Impaired MCC Obstruction Infection Inflammation Progressive, irreversible lung damage Respiratory failure
13 Chronic Therapies for Maintenance of Lung Health A Strong Recommendation for: B Recommendation for: D Recommendation against: Inhaled tobramycin Mod-severe dz Dornase alfa Mod-severe dz Inhaled tobramycin Mild-asx dz Dornase alfa Mild-asx dz Hypertonic saline Macrolides Ibuprofen Inhaled -agonists Oral steroids Age 6-18 Inhaled steroids Anti-Staph abx Insufficient Evidence to make a recommendation: Other aerosolized antibiotics N-acetyl cysteine Cromolyn Flume et al, Am J Respir Crit Care Med 2007; 176: Inhaled anticholinergics Leukotriene modifiers Oral steroids (age>18)
14 Chronic Therapies for Maintenance of Lung Health A Strong Recommendation for: Inhaled tobramycin Mod-severe dz Inhaled aztreonam Mod-severe dz Dornase alfa Mod-severe dz Ivacaftor (G551D) B Recommendation for: Inhaled tobramycin Mild-asx dz Inhaled aztreonam Mild-asx dz Dornase alfa Mild-asx dz Hypertonic saline Macrolides (with PA) Ibuprofen (<18 yrs) D Recommendation against: Oral steroids Age 6-18 Inhaled steroids Anti-Staph abx Insufficient Evidence to make a recommendation: Other aerosolized antibiotics Chronic oral anti-staph N-acetyl cysteine Cromolyn Flume et al, Am J Respir Crit Care Med 2007; 176: Mogayzel et al, Am J Respir Crit Care Med 2013; 187: Inhaled β-agonists (chronic) Inhaled anticholinergics Leukotriene modifiers Oral steroids (age>18) Macrolides (without PA)
15 Challenges in the Treatment of CF Lung Disease Gene mutations CFTR quantity CFTR function Reduced ASL Impaired MCC Dornase alfa Bronchodilators Obstruction Infection Inflammation Hydrators Antibiotics Ibuprofen, Macrolides Progressive, irreversible lung damage Respiratory failure
16 Challenges in the Treatment of CF Lung Disease Gene mutations CFTR quantity CFTR function Reduced ASL Impaired MCC Dornase alfa Bronchodilators Obstruction Infection Inflammation Hydrators Antibiotics Ibuprofen, Macrolides Progressive, irreversible lung damage Respiratory failure
17 Challenges in the Treatment Insert a normal gene of CF Lung Disease Gene mutations Fix the CFTR defect CFTR quantity CFTR function Bypass the function of CFTR Reduced ASL Impaired MCC Dornase alfa Bronchodilators Obstruction Infection Inflammation Hydrators Antibiotics Ibuprofen, Macrolides Progressive, irreversible lung damage Respiratory failure
18 Strategies to Treat Early Aspects of Pathogenesis of CF Lung Disease Replace the gene Gene Therapy
19 Gene Therapy for CF UK Cystic Fibrosis Gene Therapy Consortium Multi-dose clinical trial of gene therapy 130 patients age > 12 years First study to look at a clinical benefit Expected completion in
20 Strategies to Treat Early Aspects of Pathogenesis of CF Lung Disease Replace the gene Gene Therapy Bypass the effects of CFTR alternate channels Inhibit sodium absorption (ENaC) Stimulate chloride secretion (P 2 Y 2, CaCC)
21 Strategies to Treat Early Aspects of Pathogenesis of CF Lung Disease Replace the gene Gene Therapy Bypass the effects of CFTR alternate channels Correct the CFTR mutation CFTR modulators
22 Challenges in the Treatment of CF Lung Disease Gene mutations CFTR quantity CFTR function CFTR Potentiators (e.g. ivacaftor) Reduced ASL Impaired MCC Dornase alfa Bronchodilators Obstruction Infection Inflammation Hypertonic saline Antibiotics Ibuprofen, Macrolides Progressive, irreversible lung damage Respiratory failure
23 Ivacaftor in Patients with CF and G551D Sweat Chloride Normal: <40 mmol/l CF: >60 mmol/l Ramsey et al., NEJM 2011; 365:
24 Ivacaftor in Patients with CF and G551D Ramsey et al., NEJM 2011; 365:
25 Ivacaftor for G551D CFTR Modulation
26 Important Questions Would earlier treatment prevent CF lung disease?
27 What might we expect from earlier treatment with ivacaftor? Ramsey et al., NEJM 2011; 365: Variable Age at diagnosis (yrs) Sweat chloride (mean) FEV 1 (mean % pred) S aureus or P aeruginosa Clubbing CF-PI % 100% 71% Goubau et al., Thorax 2009; 64: CFTR-dysfunction % 65% 27%
28 Important Questions Would earlier treatment prevent CF lung disease? Will ivacaftor work for other CFTR gene mutations?
29 Ivacaftor Potentiation of CFTR Channels with Gating Mutations Yu H et al. J Cyst Fibr 2012; 11:
30 What about ivacaftor for other gene mutations? Trial of ivacaftor in subjects with CF who have a non-g551d CFTR gating mutation 1 G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D Clinicaltrials.gov: 1 NCT ;
31 Ivacaftor CFTR Modulation G551D plus age 2-5 years Other gating mutations
32 What about ivacaftor for other gene mutations? Trial of ivacaftor in subjects with CF who have a non-g551d CFTR gating mutation 1 G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D Trial of ivacaftor in subjects with R117H 2 Clinicaltrials.gov: 1 NCT ; 2 NCT
33 Ivacaftor CFTR Modulation G551D plus age 2-5 years Other gating mutations R117H
34 CFTR Gene mutations Cystic Fibrosis Foundation Patient Registry Annual Data Report. Bethesda, MD.
35 What about ivacaftor for other gene mutations? Trial of ivacaftor in subjects with CF who have a non-g551d CFTR gating mutation 1 G178R, G551S, S549N, S549R, G970R, G1244E, S1251N, S1255P, or G1349D Trial of ivacaftor in subjects with R117H 2 Not effective for df508 3 Clinicaltrials.gov: 1 NCT ; 2 NCT Flume et al., Chest 2012; 142:
36 CFTR Mutations and Quantity of CFTR Yu H et al. J Cyst Fibr 2012; 11:
37 Challenges in the Treatment of CF Lung Disease Gene mutations CFTR Correctors (e.g. VX809, VX661) CFTR quantity Reduced ASL Impaired MCC CFTR function Hypertonic saline Dornase alfa Bronchodilators Obstruction Infection Inflammation Hypertonic saline Antibiotics Ibuprofen, Macrolides Progressive, irreversible lung damage Respiratory failure
38 F508del-CFTR Activity (% wild-type-cftr) F508-CFTR C-band (normalized to GAPDH) F508-CFTR C-band (normalized to GAPDH) F508-CFTR C-band (normalized to GAPDH) A Cellular Processing of F508del-CFTR B ER C- B- A C- B- B GAPDH wt A F508 C- B- B- C- B- GAPDH CFTR Corrector C- GAPDH wt F508 CFTR-mediated Cl Flux B B Normal wt Log F508 F508del- M [VX-809] Log M [VX-809] C 0-8CFTR CFTR C- C- B- Control VX-809 Log M [VRT ] C Control Corrector molecules appear to hit an efficacy ceiling at 10-20% correction Van Goor et al. Pediatr Pulmonol 2009; 44 (S32) 3 C * VX Log M 1[V 0-9 Lo
39 CFTR Corrector Monotherapy Clancy JP et al. Thorax 2012; 67: 12-18
40 F508del-CFTR Activity (% wt-cftr) CFTR Corrector + Potentiator F508del-CFTR CFTR corrector VX Ivacaftor CFTR potentiator VX-809 alone Log M [VX-809] Van Goor et al. Pediatr Pulmonol 2009; 44 (S32)
41 Clinical Evaluation of Lumacaftor Alone and in Combination with Ivacaftor: Cohort 2 Study Design Lumacaftor Monotherapy Lumacaftor and Ivacaftor Combination n=23 lumacaftor 200 mg qd lumacaftor 200 mg qd + ivacaftor 250 mg q12h F508del homozygotes n=21 n=21 lumacaftor 400 mg qd lumacaftor 600 mg qd lumacaftor 400 mg qd + ivacaftor 250 mg q12h lumacaftor 600 mg qd + ivacaftor 250 mg q12h F508del heterozygotes n=17 n=6 Placebo Placebo + Placebo n=21 lumacaftor 600 mg qd lumacaftor 600 mg qd + ivacaftor 250 mg q12h Day -21 Day 0 Day 14 Day 28 Day 42 Day 56 n=number of patients randomized and dosed 41
42 Boyle M, presented at NACFC 2012
43 Current Status for CFTR Modulators for df508 Phase 3 studies of lumicaftor (VX-809) + ivacaftor in subjects homozygous for df508 1 Phase 2 study of VX-661 +/- ivacaftor in subjects homozygous for df508 2 Press release April 18, 2013 Dose of VX-661 n Absolute change in FEV 1 (%) Relative change in FEV 1 (%) Placebo mg mg mg * 9.0* 150 mg * 7.5** Clinicaltrials.gov: 1 NCT and NCT Clinicaltrials.gov: 2 NCT *p=0.01; **p=0.02
44 Ivacaftor CFTR Modulation G551D plus age 2-5 years Other gating mutations R117H Homozygous df508
45 Ivacaftor CFTR Modulation G551D plus age 2-5 years Other gating mutations R117H Homozygous df508 Heterozygous df508
46 Strategic Initiative for Next Generation Discovery Vertex Combinatorial approach for synergy Genzyme Mechanistic CFTR-target based approach Pfizer Mechanistic and cell based, combinational therapy Proteostasis CFTR interactome and folding environment Reata Cell based NBD stabilization McGill/Glaxo Smith Kline CFTR surface expression, mechanistic target based
47 What else is in the pipeline?
48 CFTR Correctors (e.g. VX809, VX661) Challenges in the Treatment Dornase alfa of CF Lung Disease CFTR quantity Bronchodilators Gene Therapy Gene mutations Reduced ASL Impaired MCC CFTR function Obstruction Infection Inflammation Hypertonic saline Mannitol Antibiotics Hypertonic saline Mannitol Ibuprofen, Macrolides CFTR Potentiators (e.g. ivacaftor) Progressive, irreversible lung damage Respiratory failure
49 Inhaled Mannitol in CF Aitken ML, et al. Am J Respir Crit Care Med 2012; 185:
50 CFTR Correctors (e.g. VX809, VX661) Challenges in the Treatment Dornase alfa of CF Lung Disease CFTR quantity Bronchodilators Gene Therapy Gene mutations Reduced ASL Impaired MCC CFTR function Obstruction Infection Inflammation Hypertonic saline Mannitol More antibiotic choices Change treatment strategy Antibiotics Hypertonic saline Mannitol Ibuprofen, Macrolides CFTR Potentiators (e.g. ivacaftor) Progressive, irreversible lung damage Respiratory failure
51 Inhaled antibiotics targeting Pseudomonas Antibiotic Class Aminoglycosides FDA Approved TIS (TOBI ) Bethkis TIP (Powder) Used Off-Label Gentamicin Beta-lactams AIS (Cayston ) Ceftazidime Fluoroquinolones Polymyxins Colistimethate
52 What questions remain? Do we need more antibiotic choices for Pseudomonas? Do we have the optimal regimen? Should we exercise the same strategy for other pathogens?
53 Inhaled antibiotics targeting Pseudomonas Antibiotic Class FDA Approved In Development Used Off-Label Aminoglycosides TIS (TOBI ) Bethkis Bramitob TIP (Powder) Liposomal amikacin Gentamicin Beta-lactams AIS (Cayston ) Ceftazidime Fluoroquinolones Levofloxacin aerosol Liposomal ciprofloxacin Ciprofloxacin powder Polymyxins Colistimethate
54 standard of care Dosing regimens A A A A Time A (weeks) A B B B A A A A A A Time (weeks) intermittent monotherapy continuous combination therapy continuous monotherapy
55 Assessing combination inhaled antibiotic therapy by randomized controlled trial US standard of care TIS TIS TIS Placebo Placebo Placebo TIS AIS TIS AIS TIS AIS Time (weeks) clinicaltrials.gov identifier: NCT
56 Inhaled antibiotics in CF Pathogen Prophylaxis Eradication Suppression Pseudomonas No Yes Yes Staph (MRSA)??? Stenotrophomonas??? Burkholdheria?? No? NTM???
57 Respiratory Infections in CF Patients Cystic Fibrosis Foundation Patient Registry Annual Data Report. Bethesda, MD.
58 Inhaled antibiotics targeting Staphylococcus aureus Antibiotic Class FDA Approved In Development Used Off-Label Glycopeptides Vancomycin powder (Phase 2) Vancomycin IV solution Clinicaltrials.gov identifier: NCT
59 Inflammation in Bronchioalveolor Lavage Fluid Control Cystic Fibrosis Used with permission - J. Wagener, 2004.
60 Inflammation in CF Airways Inflammation in the airways is exaggerated Neutrophil is the predominant WBC Inflammation: Causes injury to the airways (neutrophil elastase) Recruits more inflammatory cells to the airways
61 Approach to Reducing Injury from Inflammation in CF Airways Inhibit neutrophil migration to the airways SB Inhibit neutrophil elastase Augmentation of alpha-1-antitrypsin 2 1 Clinicaltrials.gov: NCT ; J Cyst Fibr 2013; 12: Clinicaltrials.gov NCT
62 CFTR Correctors (e.g. VX809, VX661) Challenges in the Treatment Dornase alfa of CF Lung Disease CFTR quantity Bronchodilators Gene Therapy Gene mutations Reduced ASL Impaired MCC CFTR function Obstruction Infection Inflammation Hypertonic saline Mannitol More antibiotic choices Change treatment strategy Antibiotics Hypertonic saline Mannitol Ibuprofen, Macrolides CFTR Potentiators (e.g. ivacaftor) Alpha-1-antitrypsin Anti-Pseudomonas Ab Progressive, irreversible lung damage Respiratory failure
63 Pa Type III Secretion System and KB001-A Cell Membrane P. aeruginosa TTSS Anti-PcrV Antibody (KB001-A) PcrV Protein Membrane disruption and exotoxin injection into cells KB001-A renders PA non-toxic by binding to the PcrV protein on the tip of the TTSS on the surface of PA and therefore prevents PA from attacking host cells through its primary toxic mechanisms. Clinicaltrials.gov identifier: NCT
64 Conclusions We have made tremendous progress in the treatment of CF patients Survival has improved Yet, patients still die too young We need new medications Recent developments offer huge potential True example of personalized medicine
65 CFTR Modulation - this is the goal Ivacaftor G551D plus age 2-5 years Other gating mutations R117H Homozygous df508 Heterozygous df508 Nonsense mutations Others
66 Conclusions But until that goal is reached: We need to use current medications more effectively Comparative effectiveness Assess treatment regimens (e.g. strategy of inhaled antibiotics) Personalize patient s treatment regimen Focus on adherence Appreciate the treatment burden
The Future of CF Therapy
The Future of CF Therapy Peter J. Mogayzel, Jr., M.D., Ph.D. Eudowood Division of Pediatric Respiratory Sciences The Johns Hopkins School of Medicine Overview The Future of CF Therapy Personalized therapy
More informationTransformational Treatments. PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs
Transformational Treatments PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs Symptom-based CF Therapies 45 Median Predicted Survival Age of US Patients with Cystic Fibrosis 41
More informationCystic Fibrosis the future
Cystic Fibrosis the future Pathophysiologic cascade Abnormal Gene Abnormal CFTR Therapy Gene replacement Protein replacement Gene read through therapy Abnormal sodium chloride & water movement through
More informationA Genetic Approach to the Treatment of Cystic Fibrosis
A Genetic Approach to the Treatment of Cystic Fibrosis Peter Mueller, PhD Chief Scientific Officer and Executive Vice President Global Research and Development Vertex Pharmaceuticals, Incorporated March
More informationEnabling CF Therapeutic Development
Enabling CF Therapeutic Development PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs No Disclosures Cystic Fibrosis In 1955 In 1955 most children with CF did not live long enough
More informationOral Cystic Fibrosis Modulators
Oral Cystic Fibrosis Modulators Goals: To ensure appropriate drug use and limit to patient populations in which they have demonstrated to be effective and safe. To monitor for clinical response for appropriate
More informationCystic Fibrosis Foundation Patient Registry 2013
5/9/2015 Targeting CFTR to Treat Cystic Fibrosis: Small Molecule Therapy Mary Ellen Kleinhenz, MD Director, UCSF Adult Cystic Fibrosis Program Professor of Medicine UCSF Division of Pulmonary, Critical
More informationYou Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM
You Can Observe a Lot By Just Watching Wayne J. Morgan, MD, CM Disclosures Genentech Epidemiological Study of Cystic Fibrosis, Scientific Advisory Group CF Foundation Data Safety Monitoring Board Registry/Comparative
More information"Management and Treatment of Patients with Cystic fibrosis (CF)
"Management and Treatment of Patients with Cystic fibrosis (CF) Dr. Malena Cohen-Cymberknoh Pediatric Pulmonology and CF Center Hadassah Hebrew-University Medical Center Jerusalem, Israel Afula, March
More informationPediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives.
Disclosure Dr Donna Willey Courand receives research support from Cystic Fibrosis Therapeutics The Cystic Fibrosis Foundation Children with Special Health Care Needs Cystic Fibrosis 05: Improving Survival
More informationCYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE
CYSTIC FIBROSIS Madhu Pendurthi MD MPH Staff Physician, Mercy Hospital Springfield, MO NO CONFLICT OF INTEREST TO DISCLOSE OBJECTIVES Epidemiology of Cystic Fibrosis (CF) Genetic basis and pathophysiology
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cystic Fibrosis Transmembrane Page 1 of 11 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cystic Fibrosis Transmembrane Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Prime Therapeutics
More informationPharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis
Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis Federico Goodsaid Vice President Strategic Regulatory Intelligence Vertex Pharmaceuticals Is there
More informationRespiratory Pharmacology: Treatment of Cystic Fibrosis
Respiratory Pharmacology: Treatment of Cystic Fibrosis Dr. Tillie-Louise Hackett Department of Anesthesiology, Pharmacology and Therapeutics University of British Columbia Associate Head, Centre of Heart
More informationCF: Understanding the Biology Curing the Disease
CF: Understanding the Biology Curing the Disease Scott H. Donaldson, MD Associate Professor of Medicine Director, Adult CF Care Center University of North Carolina at Chapel Hill Defining the path Drilling
More informationA Cure for All: Leaving No One Behind. Assuring Effective Therapies for All Patients with Cystic Fibrosis
A Cure for All: Leaving No One Behind Assuring Effective Therapies for All Patients with Cystic Fibrosis Topics for Today s Presentation Demographics of the CF patient population in the modulator era
More informationTHE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)
THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks for Vertex
More informationWhat is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF
What is Cystic Fibrosis? CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Chronic, progressive and life limiting autosomal recessive genetic disease characterized by chronic
More informationNACFC investor meeting. Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC November 2017 Copyright 2017 Galapagos NV
NACFC investor meeting Dr Katja Conrath, Therapeutic Head CF Dr Piet Wigerinck, CSO NACFC 2017 2 November 2017 Copyright 2017 Galapagos NV Disclaimer This presentation contains forward-looking statements,
More informationPA Update: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Moss RB, Flume PA, Elborn JS, et al, on behalf
More informationOpening Doors to CF Clinical Research: Change is Coming
Opening Doors to CF Clinical Research: Change is Coming Disclosures Contracts with sponsors for clinical trials conducted at UNC-Chapel Hill: CFFT NIH/NHLBI AbbVie Inc. Aptalis Pharma US, Inc. Janssen
More informationCystic Fibrosis Care at the University of Florida
Cystic Fibrosis Care at the University of Florida Objectives To introduce you to the University of Florida CF Center To review center specific data for the UF pediatric CF Center To review current status
More informationBronchiectasis. Grant Waterer. Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago
Bronchiectasis Grant Waterer MBBS PhD MBA FRACP FCCP Professor of Medicine, University of Western Australia Adjunct Professor of Medicine, Northwestern University, Chicago Conflicts of Interest I have
More informationPharmacy Policy Bulletin
Pharmacy Policy Bulletin Title: Policy #: Cystic Fibrosis Agents (Kalydeco, Orkambi ) Rx.01.117 Application of pharmacy policy is determined by benefits and contracts. Benefits may vary based on product
More informationDisclosures. Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy 10/28/2016
Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy Susanna A McColley, MD Associate Chief Research Officer Stanley Manne Children s Research Institute
More informationDrug Use Criteria: Ivacaftor (Kalydeco ) and Lumacaftor/Ivacaftor (Orkambi )
Texas Vendor Program Use Criteria: (Kalydeco ) and Lumacaftor/ (Orkambi ) Publication History Developed: October 2012 Revised: December 2017; February 2016; June 2014. Notes: Information on indications
More informationClass Update: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGoals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy
CYSTIC FIBROSIS Lynne M. Quittell, M.D. Director, CF Center Columbia University Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy What is Cystic Fibrosis? Chronic, progressive
More informationCystic fibrosis: From childhood to adulthood. Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel
Cystic fibrosis: From childhood to adulthood Eitan Kerem Department of Pediatrics and CF Center Hadassah University Hospital Jerusalem Israel Vas deference H 2 O Cl - Na + H 2 O Na + Cl - Cl - Cl -
More informationCystic Fibrosis Module #2: Chronic Medications: Changing the Course of Cystic Fibrosis. Chronic Medications: Changing the Course of Cystic Fibrosis
Module #2: Chronic Medications: Changing the Course of Chronic Medications: Changing the Course of Dr. Jeffery T. Zobell, Pharm.D., BCPPS Dr. David C. Young, Pharm.D. Objectives Discuss current guideline
More informationKalydeco. Kalydeco (ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.03 Subject: Kalydeco Page: 1 of 6 Last Review Date: November 30, 2018 Kalydeco Description Kalydeco
More informationHOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF
HOW DISEASE ALTERING THERAPY IS CHANGING THE GOALS OF TREATMENT IN CF Peter D. Sly MBBS, MD, FRACP, DSc OUTLINE Goals of CF treatment Drivers of early disease neutrophilic inflammation oxidative stress
More informationCCLI. Bronchiectasis Treatment Antibiotics. Charles Haworth. Physician / Patient Conference, Georgetown University, May 2017
Physician / Patient Conference, Georgetown University, May 2017 Bronchiectasis Treatment Antibiotics Charles Haworth CCLI Cambridge Centre for Lung Infection Disclosures Educational talks and / or consultancy
More informationPulmonary Exacerbations:
Pulmonary Exacerbations: Better Understanding Needed Michael Tracy, MD Clinical Assistant Professor Pediatric Pulmonary CF Pulmonary Exacerbations Definition Importance Causes Treatment Research opportunities
More informationCystic fibrosis: hitting the target
Cystic fibrosis: hitting the target Heartland Collaborative Annual Meeting Friday, October 5, 2012 Thomas Ferkol MD 1938 1953 Cystic fibrosis: a historical timeline Cystic fibrosis (CF) of the pancreas
More informationNorth American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics
Proof of Concept Study to Demonstrate the Effects of QR-010 on Nasal Potential Difference in Subjects With Cystic Fibrosis with the F508del CFTR Mutation Noreen R Henig, MD Chief Development Officer ProQR
More informationIVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER
IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER February 21, 2014 U.S. Food and Drug Administration Approves KALYDECO (ivacaftor) for Use in Eight
More informationTreatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes
Journal of Cystic Fibrosis 12 (2013) 461 467 www.elsevier.com/locate/jcf Original Article Treatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes Gregory
More informationPalliative and Supportive Care in Cystic Fibrosis
Palliative and Supportive Care in Cystic Fibrosis Dr William Flight Consultant in Respiratory Medicine Oxford Adult Cystic Fibrosis Centre 27 th January 2017 Overview 1. Cystic Fibrosis Clinical Aspects
More informationCystic fibrosis: From the gene to the disease
Cystic fibrosis: From the gene to the disease Christiane Knoop, MD, PhD Institut de Mucoviscidose de l ULB Hôpital Erasme christiane.knoop@erasme.ulb.ac.be Cystic fibrosis «The infant that tastes of salt
More information10/05/2017. Learning Objectives. Etiology and Prevalence. Diagnosis of Cystic Fibrosis. Disease of Childhood? Survival in Cystic Fibrosis
Management of the Cystic Fibrosis Patient Jessica Goggin, MAS, RN Nurse Manager UC San Diego Adult Cystic Fibrosis Program Learning Objectives 1. Describe the symptoms associated with Cystic Fibrosis (CF).
More informationTargeted therapies to improve CFTR function in cystic fibrosis
Brodlie et al. Genome Medicine (2015) 7:101 DOI 10.1186/s13073-015-0223-6 REVIEW Targeted therapies to improve CFTR function in cystic fibrosis Malcolm Brodlie 1*, Iram J. Haq 2, Katie Roberts 2 and J.
More informationBriefing Document. FDA Pulmonary - Allergy Drugs Advisory Committee
FDA Advisory Committee Briefing Materials Page 1 of 157 Briefing Document FDA Pulmonary - Allergy Drugs Advisory Committee Ivacaftor for the Treatment of Cystic Fibrosis in Patients Age 6 Years and Older
More informationAppendix D Clinical specialist statement template
Appendix D Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of pseudomonas lung infection in cystic fibrosis Thank you for agreeing to give us a statement on your organisation
More informationExploring New Advances and Best Practices to Personalize Therapy and Improve Lung Function in Cystic Fibrosis
CME/CNE/CPE Exploring New Advances and Best Practices to Personalize Therapy and Improve Lung Function in Cystic Fibrosis Course Director Jerry Nick, MD National Jewish Health University of Colorado Denver,
More informationLumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects
601934TAR0010.1177/1753465815601934Therapeutic Advances in Respiratory DiseaseKuk and Taylor-Cousar research-article2015 Therapeutic Advances in Respiratory Disease Review Lumacaftor and ivacaftor in the
More informationPseudomonas aeruginosa eradication guideline
SCOTTISH PAEDIATRIC CYSTIC FIBROSIS MCN Pseudomonas aeruginosa eradication guideline Date Created: 27 th June 2013 Date Approved by Steering Group: 30 th May 2014 Date of Review: 31 st May 2016 Lead Author:
More informationClass Update with New Drug Evaluation: Oral Cystic Fibrosis Modulators
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationCystic fibrosis (CF) is the most frequent. Ivacaftor treatment in patients with cystic REVIEW. Isabelle Sermet-Gaudelus
Eur Respir Rev 2013; 22: 127, 66 71 DOI: 10.1183/09059180.00008512 CopyrightßERS 2013 REVIEW Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation Isabelle Sermet-Gaudelus ABSTRACT:
More informationTreatment of lung infection in patients with cystic fibrosis: Current and future strategies,
Journal of Cystic Fibrosis 11 (2012) 461 479 www.elsevier.com/locate/jcf Review Treatment of lung infection in patients with cystic fibrosis: Current and future strategies, Gerd Döring a,, Patrick Flume
More informationRecently, the cystic fibrosis (CF) community celebrated the 25th
focused review A new era of personalized medicine for cystic fibrosis at last! Bradley S Quon MD MSc FRCPC 1,2, Pearce G Wilcox MD FRCPC 1,2 BS Quon, PG Wilcox. A new era of personalized medicine for cystic
More informationCystic Fibrosis Diagnosis and Treatment
Cystic Fibrosis Diagnosis and Treatment Financial Disclosures Personal financial relationships with commercial interests relevant to medicine, within the past 3 years: NJH site PI for AstraZeneca. As faculty
More informationTHE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)
THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks of Vertex
More informationNew Drug Evaluation: Lumacaftor/Ivacaftor
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLRI Children s Hospital
Title: Prescribing in Cystic Fibrosis Page 1 of 10 LRI Children s Hospital Prescribing in Cystic Fibrosis Staff relevant to: Clinical staff working within the UHL Children s Hospital. Team & AWP approval
More informationWe strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis
Nivalis Therapeutics, Inc., October 2015 Analyst Breakfast at NACFC We strive to develop innovative solutions that improve and extend the lives of people with cystic fibrosis Disclaimer Regarding Forward
More informationNational Horizon Scanning Centre. Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis. April 2008
Mannitol dry powder for inhalation (Bronchitol) for cystic fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationAt-A-Glance report 2014
At-A-Glance report 14 Cystic Fibrosis in Europe Facts and Figures 14 The European Cystic Fibrosis Society Patient Registry (ECFSPR) is happy to present this report with key information about how cystic
More informationAt-A-Glance report 2013
At-A-Glance report 213 Cystic Fibrosis in Europe Facts and Figures 213 The European Cystic Fibrosis Society Patient Registry (ECFSPR) is happy to present this report with key information about how cystic
More information4.6 Small airways disease
4.6 Small airways disease Author: Jean-Marc Fellrath 1. INTRODUCTION Small airways are defined as any non alveolated and noncartilaginous airway that has an internal diameter of 2 mm. Several observations
More informationCystic Fibrosis Update
Cystic Fibrosis Update More than Decades of Discovery Dr. Raj Padman Professor of Pediatric TJU Board certified in Pediatrics, Pulmonology, and Sleep Medicine Dupont, Kosciusko Community, Lutheran, Rehabilitation,
More informationEfficacy of NaCl nebulized hypertonic solutions in cystic fibrosis
Acta Biomed 2014; Vol. 85, Supplement 4: 10-18 Mattioli 1885 Original article Efficacy of NaCl nebulized hypertonic solutions in cystic fibrosis Azienda Ospedaliero Universitaria Policlinico, DAI Scienze
More informationMarcos I. Restrepo, MD, MSc, FCCP
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationCYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions
CYSTIC FIBROSIS FOUNDATION INFO-POD Information You Need to Make Benefits Decisions Issue 1: Hypertonic Saline Summary: Preserving lung function is a crucial element in the care of the individual with
More informationNorth American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics
Proof of Concept Study to Demonstrate the Effects of QR-010 on Nasal Potential Difference in Subjects With Cystic Fibrosis with the F508del CFTR Mutation Noreen R Henig, MD Chief Development Officer ProQR
More informationMichael P. Boyle, MD. Senior Vice President of Therapeutics Development Cystic Fibrosis Foundation #NACFC
#NACFC Michael P. Boyle, MD Senior Vice President of Therapeutics Development Cystic Fibrosis Foundation #NACFC Cystic Fibrosis Foundation Meetings Team Cynthia Adams, HMCC, Senior Director of Meetings
More informationA Quick Guide to the. I507del. Mutation CFTR SCIENCE
A Quick Guide to the I507del Mutation CFTR SCIENCE 2016 Vertex Pharmaceuticals Incorporated VXR-HQ-02-00045a(1) 03/2016 Loss of CFTR activity is the underlying cause of cystic fibrosis (CF) 1 Spectrum
More informationEfficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis
Efficacy of Pseudomonas aeruginosa eradication regimens in bronchiectasis Vallières, E., Tumelty, K., Tunney, M. M., Hannah, R., Hewitt, O., Elborn, J. S., & Downey, D. G. (2017). Efficacy of Pseudomonas
More informationNew and investigational treatments in cystic fibrosis
Therapeutic Advances in Respiratory Disease Review New and investigational treatments in cystic fibrosis Mangala Narasimhan and Rubin Cohen Ther Adv Respir Dis (2011) 5(4) 275 282 DOI: 10.1177/ 1753465811398267!
More informationCystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL
Cystic Fibrosis as it relates to the neonate MARIANNE MUHLEBACH, MD PROFESSOR, DEPT. PEDIATRICS UNC CHAPEL HILL Objectives: At the end of the presentation the listeners will Be able to describe neonatal
More informationCystic Fibrosis: KOL Insight [2017]
Cystic Fibrosis: KOL Insight [2017] Cystic Fibrosis: KOL Insight [2017] BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 5 November 2014 KALYDECO 150 mg, film-coated tablet B/56 (CIP: 34009 266 060 5 3) Applicant: VERTEX INN ATC code Reason
More informationScottish Paediatric Cystic Fibrosis MCN. Protocols / Guidelines. Ivacaftor: A guideline for use in paediatric CF patients in Scotland
Scottish Paediatric Cystic Fibrosis MCN Protocols / Guidelines Ivacaftor: A guideline for use in paediatric CF patients in Scotland Authors: Dr Carol Dryden Dr Jane Wilkinson Miss Julie Crocker, Registered
More informationInhalational antibacterial regimens in non-cystic fibrosis patients. Jeff Alder Bayer HealthCare
Inhalational antibacterial regimens in non-cystic fibrosis patients Jeff Alder Bayer HealthCare Alder - Inhaled therapy for non-cf - EMA 25-26 Oct 2012 1 Inhalational antibacterials: two approaches 1.
More informationPediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives
Nationwide Newborn Screening for Cystic Fibrosis: Finally Creating an Opportunity for All Patients to Have Better Outcomes Philip M Farrell, MD, PhD* University of Wisconsin-Madison *No disclosures other
More informationMolecular Basis of Personalized Therapies for CF: Can We Treat All Patients?
CF Europe Meeting Molecular Basis of Personalized Therapies for CF: Can We Treat All Patients? Margarida D Amaral Brussels, 13 June 2015 The CF Pathogenesis Cascade 2 Defective CF Genes Deficient CFTR
More informationNON-CYSTIC FIBROSIS BRONCHIECTASIS
NON-CYSTIC FIBROSIS BRONCHIECTASIS MARK L. METERSKY, MD PROFESSOR OF MEDICINE UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE FARMINGTON, CT Mark Metersky, MD, FCCP, FACP is a Professor of Medicine at the
More informationCase Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis?
Names: Date: Case Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis? Dr. Weyland examined a six month old infant that had been admitted to University Hospital earlier in the
More informationArikace (Preclinical Summary)
Full analyses of data from two phase II blinded and placebo-controlled studies of nebulized liposomal amikacin for inhalation (Arikace ) in the treatment of cystic fibrosis patients with chronic Pseudomonas
More informationOverview of Cystic fibrosis in children. Apeksha Sathyaprasad, MD Pediatric pulmonologist
Overview of Cystic fibrosis in children Apeksha Sathyaprasad, MD Pediatric pulmonologist No conflicts of interest OBJECTIVES Review pathophysiology of pulmonary disease in cystic fibrosis Review diagnostic
More informationDisclosures. Learning Objectives. What is Cystic Fibrosis? Background
39 th National Conference on Pediatric Health Care March 19-22, 2018 CHICAGO Disclosures The Vision and the Journey of Cystic Fibrosis: Newborn Screening to Breakthrough Therapy March 20, 2018 Cynthia
More informationLumacaftor Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
The new england journal of medicine Original Article Lumacaftor Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR C.E. Wainwright, J.S. Elborn, B.W. Ramsey, G. Marigowda, X. Huang,
More information(<40 and 40) and screening ppfev 1. , were done for patients with baseline ppfev 1
Efficacy and safety of lumacaftor/ivacaftor combinion therapy in pients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis J Stuart Elborn, Bonnie W Ramsey,
More informationEradication regimens for early or recurrent Pseudomonas aeruginosa infection
Eradication regimens for early or recurrent Pseudomonas aeruginosa infection The Leeds Method of Management. April, 2008. Cystic fibrosis and eradication therapy for early or recurrent Pseudomonas aeruginosa
More informationINHALED ANTIBIOTICS THERAPY IN NON-CF LUNG DISEASE
INHALED ANTIBIOTICS THERAPY IN NON-CF LUNG DISEASE Hannah Blau MBBS Pulmonary Institute and Graub CF Center SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL Chipap 18 th February 2015 Inhaled antibiotic therapy:
More informationJournal Club The ELITE Trial. Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010
Journal Club The ELITE Trial Sandra Katalinic, Pharmacy Resident University Hospital of Northern British Columbia April 28, 2010 Overview Journal article Title, journal, authors, funding Abstract Introduction
More informationClinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations)
Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (named mutations) Reference: NHS England: A01/P/c NHS England INFORMATION READER BOX Directorate Medical Commissioning Operations Patients and
More informationClinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (all ages)
Clinical Commissioning Policy: Levofloxacin nebuliser solution for chronic Pseudomonas lung infection in cystic fibrosis (all ages) NHS England Reference: 1732P NHS England INFORMATION READER BOX Directorate
More informationA Case of Cystic Fibrosis
Name(s) Date A Case of Cystic Fibrosis Dr. Weyland examined a six month old infant that had been admitted to University Hospital earlier in the day. The baby's parents had brought young Zoey to the emergency
More informationivacaftor 150mg film-coated tablets (Kalydeco ) SMC No. (1193/16) Vertex Pharmaceuticals (Europe) Ltd
ivacaftor 150mg film-coated tablets (Kalydeco ) SMC No. (1193/16) Vertex Pharmaceuticals (Europe) Ltd 04 November 2016 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationOpinion 7 November 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 7 November 2012 KALYDECO 150 mg film-coated tablets B/56 (CIP code: 34009 266 060 5 3) Applicant: VERTEX INN ATC Code
More informationOrkambi. Orkambi (lumacaftor/ivacaftor) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.45.06 Subject: Orkambi Page: 1 of 6 Last Review Date: November 30, 2018 Orkambi Description Orkambi (lumacaftor/ivacaftor)
More informationKey points. Credit: Sheffield Teaching Hospitals NHS Foundation Trust
Key points There have been significant advances in both inhalation medicines and delivery devices with intelligent nebulisers and dry-powder inhalers becoming commonplace in CF care. Inhaled medicines
More informationPhase 1 and 2 Data for Triple Combination Regimens Demonstrate Improvements in Lung Function and Other Measures in CF Patients
Phase 1 and 2 Data for Triple Combination Regimens Demonstrate Improvements in Lung Function and Other Measures in CF Patients July 18, 2017 Agenda Introduction Michael Partridge, VP Investor Relations
More informationJournal of the COPD Foundation The COPD Pipeline XXXVI Nicholas Gross, MD, PhD 1
320 COPD Pipeline Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation The COPD Pipeline XXXVI Nicholas Gross, MD, PhD 1 Abbreviations: chronic obstructive pulmonary disease, COPD; Food
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
More informationOpinion 18 December TADIM 1 million international units (IU) of powder for nebuliser solution Box30 vials (CIP: )
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 TADIM 1 million international units (IU) of powder for nebuliser solution Box30 vials (CIP: 34009
More information